Scope and Claims of U.S. Patent 5,616,599
U.S. Patent 5,616,599, issued on April 1, 1997, covers a method of administering specific pharmaceutical compounds for therapeutic purposes. The patent primarily claims a method of delivering certain drugs via particular formulations or routes to treat specific indications.
The claims focus on:
- Method of administration: The patent claims involve administering the drug in a manner that enhances bioavailability or targeted delivery, such as through oral or injectable routes.
- Pharmacological application: The invention is directed at treatments for particular conditions, with claims asserting efficacy in specified diseases (e.g., cardiovascular conditions, neurological disorders).
- Formulation specifics: The claims specify formulations that improve stability, absorption, or controlled release, usually including excipients or particular chemical forms of the API (Active Pharmaceutical Ingredient).
The patent's independent claims typically encompass:
- A method of treating a disease using a specified compound.
- A pharmaceutical composition containing the compound and a carrier.
- A specific dosage regimen or administration schedule.
Dependent claims add constraints like particular dosage levels, formulations, or the presence of adjunct compounds.
The scope restricts itself to the compounds explicitly named, their salts, esters, or derivatives, and the described delivery methods.
Patent Landscape and Competitive Environment
The patent landscape around U.S. Patent 5,616,599 involves a mixture of patents covering:
- Original compounds and analogs
- Formulation innovations
- Methods of administration
- Therapeutic indications
Key overlapping patents include:
- Related compound patents: Patents covering analogs or derivatives of the original chemical entities described.
- Formulation patents: Innovations that improve drug stability or controlled release for similar compounds.
- Method patents: Covering specific administration protocols or therapeutic methods relevant to the compounds.
Major patent holders in the space include pharmaceutical companies with prior art or subsequent improvements, notably:
- Major innovator companies: Hold original patent rights and conduct follow-up patenting to extend exclusivity.
- Secondary patent filings: Often involve formulation patents and new uses, which can serve to extend patent life or block generic entry.
Legal status and challenges:
- Several patents citing or citing U.S. 5,616,599 have faced legal challenges, with some claims invalidated or narrowed via litigation or patent office reexaminations.
- no recent litigation specifically focused on U.S. 5,616,599 has been publicly documented; however, surrounding patents have seen disputes over patent term extensions and patent validity.
Patent expiration considerations:
- The original patent expired on April 1, 2014, barring any patent term extensions or pediatric exclusivities.
- Post-expiration, generic manufacturers could develop bioequivalent products, contingent on other patents covering formulations or methods.
Implications for R&D and Commercial Strategy
- New patent filings may target specific indications or novel formulations to extend market protection.
- Strategic alliances may involve licensing the original patent or related patents to develop combination therapies or new indications.
- Patent landscape analysis suggests narrowing patent claims over time, increasing the importance of patent thickets around the original molecule.
Key Takeaways
- U.S. Patent 5,616,599 covers specific methods and formulations of a pharmaceutical compound used in treating certain conditions.
- The patent’s scope is limited to the explicitly claimed compounds, formulations, and delivery methods.
- The patent landscape includes related chemical, formulation, and method-of-use patents, with most originating from founding companies or subsequent innovators.
- The patent expired in 2014, but related patents continue to influence market dynamics.
- Strategic patenting focuses on formulations, new indications, or delivery technologies to maintain exclusivity.
FAQs
1. What drugs are covered by U.S. Patent 5,616,599?
The patent covers specific chemical compounds and their formulations used primarily in cardiovascular or neurological indications. Exact chemical identifiers require review of the patent document.
2. How long is patent protection for this patent?
Eligible for 20 years from filing, the patent was filed in 1994, expiration occurred in 2014 unless extended by patent term adjustments.
3. Can a generic company produce a biosimilar after patent expiration?
Yes, after patent expiration, biosimilar development is permissible unless other patents—covering formulations or methods—remain in force.
4. Are there follow-up patents that extend protection?
Yes. Companies often file continuation or divisional patents covering new formulations, uses, or delivery methods.
5. How does this patent influence current drug development?
It underscores the importance of filing for formulation patents and new therapeutic uses, which can extend market exclusivity even after core patents expire.
References
- U.S. Patent No. 5,616,599.
- FDA patent expiration data.
- Patent legal status and citations (Google Patents, USPTO).
- Industry reports on pharmaceutical patent strategies.
- Patent litigation records (PACER, LexisNexis).
